114 related articles for article (PubMed ID: 26739636)
21. Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma.
Tomuleasa C; Soritau O; Rus-Ciuca D; Pop T; Todea D; Mosteanu O; Pintea B; Foris V; Susman S; Kacsó G; Irimie A
J Gastrointestin Liver Dis; 2010 Mar; 19(1):61-7. PubMed ID: 20361077
[TBL] [Abstract][Full Text] [Related]
22. CD133(+) CD44(+) Cells Mediate in the Lung Metastasis of Osteosarcoma.
He A; Yang X; Huang Y; Feng T; Wang Y; Sun Y; Shen Z; Yao Y
J Cell Biochem; 2015 Aug; 116(8):1719-29. PubMed ID: 25736420
[TBL] [Abstract][Full Text] [Related]
23. Niche Mimicking for Selection and Enrichment of Liver Cancer Stem Cells by Hyaluronic Acid-Based Multilayer Films.
Lee IC; Chuang CC; Wu YC
ACS Appl Mater Interfaces; 2015 Oct; 7(40):22188-95. PubMed ID: 26379083
[TBL] [Abstract][Full Text] [Related]
24. CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor).
Choijamts B; Jimi S; Kondo T; Naganuma Y; Matsumoto T; Kuroki M; Iwasaki H; Emoto M
Stem Cells; 2011 Oct; 29(10):1485-95. PubMed ID: 21919130
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.
Currie MJ; Beardsley BE; Harris GC; Gunningham SP; Dachs GU; Dijkstra B; Morrin HR; Wells JE; Robinson BA
Hum Pathol; 2013 Mar; 44(3):402-11. PubMed ID: 23036368
[TBL] [Abstract][Full Text] [Related]
26. AFB1 hepatocarcinogenesis is via lipid peroxidation that inhibits DNA repair, sensitizes mutation susceptibility and induces aldehyde-DNA adducts at p53 mutational hotspot codon 249.
Weng MW; Lee HW; Choi B; Wang HT; Hu Y; Mehta M; Desai D; Amin S; Zheng Y; Tang MS
Oncotarget; 2017 Mar; 8(11):18213-18226. PubMed ID: 28212554
[TBL] [Abstract][Full Text] [Related]
27. CD133 and ALDH may be the molecular markers of cholangiocarcinoma stem cells.
Wang M; Xiao J; Jiang J; Qin R
Int J Cancer; 2011 Apr; 128(8):1996-7. PubMed ID: 20568110
[No Abstract] [Full Text] [Related]
28. DNA damage checkpoint response to aflatoxin B1.
Engin AB; Engin A
Environ Toxicol Pharmacol; 2019 Jan; 65():90-96. PubMed ID: 30594067
[TBL] [Abstract][Full Text] [Related]
29. Biology and clinical implications of CD133(+) liver cancer stem cells.
Ma S
Exp Cell Res; 2013 Jan; 319(2):126-32. PubMed ID: 22999864
[TBL] [Abstract][Full Text] [Related]
30. Stemness characteristics of fibrolamellar hepatocellular carcinoma: immunohistochemical analysis with comparisons to conventional hepatocellular carcinoma.
Zenali MJ; Tan D; Li W; Dhingra S; Brown RE
Ann Clin Lab Sci; 2010; 40(2):126-34. PubMed ID: 20421623
[TBL] [Abstract][Full Text] [Related]
31. BMP4 administration induces differentiation of CD133+ hepatic cancer stem cells, blocking their contributions to hepatocellular carcinoma.
Zhang L; Sun H; Zhao F; Lu P; Ge C; Li H; Hou H; Yan M; Chen T; Jiang G; Xie H; Cui Y; Huang X; Fan J; Yao M; Li J
Cancer Res; 2012 Aug; 72(16):4276-85. PubMed ID: 22773665
[TBL] [Abstract][Full Text] [Related]
32. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma.
Kohga K; Tatsumi T; Takehara T; Tsunematsu H; Shimizu S; Yamamoto M; Sasakawa A; Miyagi T; Hayashi N
J Hepatol; 2010 Jun; 52(6):872-9. PubMed ID: 20395004
[TBL] [Abstract][Full Text] [Related]
33. [Progress and prospects in cancer stem cell research for hepatocellular carcinoma].
Xu W; Cao L; Yin ZF
Ai Zheng; 2009 Sep; 28(9):1004-8. PubMed ID: 19728923
[TBL] [Abstract][Full Text] [Related]
34. Cancer stem cell differentiation: TGFβ1 and versican may trigger molecules for the organization of tumor spheroids.
Oktem G; Sercan O; Guven U; Uslu R; Uysal A; Goksel G; Ayla S; Bilir A
Oncol Rep; 2014 Aug; 32(2):641-9. PubMed ID: 24927163
[TBL] [Abstract][Full Text] [Related]
35. Differential Expression of Cancer Stem Cell Markers ALDH1 and CD133 in Various Lung Cancer Subtypes.
Roudi R; Korourian A; Shariftabrizi A; Madjd Z
Cancer Invest; 2015; 33(7):294-302. PubMed ID: 26046383
[TBL] [Abstract][Full Text] [Related]
36. Surface markers of hepatocellular cancer stem cells and their clinical potential.
Feng D; Wang N; Hu J; Li W
Neoplasma; 2014; 61(5):505-13. PubMed ID: 24712843
[TBL] [Abstract][Full Text] [Related]
37. Identification and characterization of tumorigenic liver cancer stem/progenitor cells.
Ma S; Chan KW; Hu L; Lee TK; Wo JY; Ng IO; Zheng BJ; Guan XY
Gastroenterology; 2007 Jun; 132(7):2542-56. PubMed ID: 17570225
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications.
Marquardt JU; Factor VM; Thorgeirsson SS
J Hepatol; 2010 Sep; 53(3):568-77. PubMed ID: 20646772
[TBL] [Abstract][Full Text] [Related]
39. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb.
Zhang J; Luo N; Luo Y; Peng Z; Zhang T; Li S
Int J Oncol; 2012 Mar; 40(3):747-56. PubMed ID: 22025269
[TBL] [Abstract][Full Text] [Related]
40. FOXM1-Induced PRX3 Regulates Stemness and Survival of Colon Cancer Cells via Maintenance of Mitochondrial Function.
Song IS; Jeong YJ; Jeong SH; Heo HJ; Kim HK; Bae KB; Park YH; Kim SU; Kim JM; Kim N; Ko KS; Rhee BD; Han J
Gastroenterology; 2015 Oct; 149(4):1006-16.e9. PubMed ID: 26091938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
